Classification framework shows 79% to 98% performance for oral squamous cell carcinoma on histopathological images
AI Learns to Ignore Stains to Spot Mouth Cancer
A computer-aided classification study evaluated a framework combining staining-bias suppression and structured multiple-instance aggregation…
New AI technology learns to ignore stain colors, helping doctors spot mouth cancer more accurately even when lab dyes vary.
Radiotherapy de-escalation strategies show reduced toxicity but modest clinical benefits in head and neck cancer cohorts
Smarter Radiation for Head and Neck Cancer May Spare Patients Misery
This narrative review examines radiotherapy de-escalation strategies for head and neck squamous cell carcinoma and HPV-related oropharyngeal…
Doctors are testing gentler radiation plans that protect quality of life for people with throat, mouth, and neck cancers facing harsh side e…
Phase 1b ABBV-368 combinations in recurrent/metastatic HNSCC show 14.3% overall response rate
Early study of ABBV-368 plus other drugs showed limited tumor response in head and neck cancer patients
This phase 1b, multicenter, open-label study enrolled 30 adults with recurrent or metastatic head and neck squamous cell carcinoma across th…
Early trials of ABBV-368 combined with other drugs showed limited tumor shrinkage in head and neck cancer patients despite a generally safe …
Timing of surgery after neoadjuvant chemoimmunotherapy impacts survival in operable esophageal squamous cell carcinoma
Shrink Faster, Live Longer: Timing Saves Lives in Esophageal Cancer
This multicenter retrospective cohort study evaluated 163 patients with operable esophageal squamous cell carcinoma receiving neoadjuvant…
Faster tumor shrinkage and surgery within six weeks of treatment predict longer survival for esophageal cancer patients receiving new therap…
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab
A Simple Blood Ratio May Predict Cancer Drug Success
This Phase II clinical trial evaluated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving combine…
A low white blood cell ratio found in blood tests predicts better survival and treatment response for advanced head and neck cancer patients…
Phase 3 trial compares IMPT versus IMRT plus cisplatin in locally advanced oropharyngeal squamous cell carcinoma
The Pricier Radiation Did Not Beat Standard Radiation for Throat Cancer
This Phase 3 randomized controlled trial enrolled 205 patients with locally advanced oropharyngeal squamous cell carcinoma across 20 UK NHS …
A large UK trial found that precision proton radiation gave similar results to standard X-ray radiation, meaning the older treatment remains…
Breg-related gene signature predicts survival and immune landscape in head and neck squamous cell carcinoma
Your Immune System Holds a Hidden Clue to Head and Neck Cancer Survival
This cohort study analyzed patients with head and neck squamous cell carcinoma (HNSCC) using bioinformatics data from TCGA and GEO databases…
A new eight-gene test predicts head and neck cancer survival better than standard measures, helping doctors identify which patients might be…
Regional motif diversity score in cfDNA predicts pembrolizumab response in head and neck cancer
Can a DNA pattern predict who will heal from head and neck cancer immunotherapy?
A phase II trial in 68 patients with locally advanced, resectable HNSCC found that a regional motif diversity score (rMDS) in cell-free DNA …
A new DNA pattern in blood can reliably predict which head and neck cancer patients will respond to immunotherapy and live longer without th…
PD-1 inhibitors + chemo improve OS, PFS, ORR in first-line advanced ESCC; benefit limited in PD-L1 CPS <1
Who benefits most from new esophageal cancer treatment? Most patients do, except one group
A meta-analysis of 8 RCTs (n=4702) found first-line PD-1 inhibitors plus chemotherapy significantly improved OS (HR=0.68, 95% CI: 0.63-0.74;…
For most advanced esophageal cancer patients, adding immunotherapy to chemotherapy extends life and shrinks tumors, but those with low PD-L1…
Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC
Phase 3 trial tests pembrolizumab with or without lenvatinib for advanced head and neck cancer
A phase 3 randomized controlled trial enrolled 511 patients with PD-L1 selected recurrent or metastatic head and neck squamous cell carcinom…
A completed Phase 3 trial tested pembrolizumab with or without lenvatinib for advanced head and neck cancer, but detailed results are not ye…